Shots:
- The Chinese NMPA has approved Zai lab‘s Tivdak for the treatment of adults with recurrent or metastatic cervical cancer with disease progression on or after CT
- Approval was backed by the global P-III (innovaTV 301) trial evaluating Tivdak vs CT alone, which met its 1EP of improved OS in the IIT population
- In the Chinese pts, Tivdak showed a 45% reduction in the risk of death, with OS benefits remaining consistent regardless of prior anti-PD-(L)1 therapy, which had been received by 54.1% of pts
Ref: Businesswire | Image: Zai Lab | Press Release
Related News: Zai Lab’s ZL-1310 Secures the US FDA’s Orphan Drug Designation to Treat Small Cell Lung Cancer (SCLC)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
